One interesting previous case law is the Integra case, where the defendant did not use the patented products for making substitution pharmaceutical but as research tools to develop a new drug in a preclinical trial and data was not even submitted in the IND to the FDA. Would you think the Bolar Exception apply in such act? Read The Supreme Court ruling.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.